In the New Approach Rivaroxaban Inhibition of Factor Xa in a Global Trial versus ASA to Prevent Embolism in Embolic Stroke of Undetermined Source (NAVIGATE ESUS) trial, 15 mg rivaroxaban was compared with 100 mg ASA in patients with recent non-cardioembolic IS. Here, F10 is linked to stroke disorder.